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Abstract: Reaction of sulfacetamide with arylsulfonyl isocyanates afforded a series of derivatives which
were used as ligands (as conjugate bases) for the preparation of metal complexes containing Ag(I) and Zn(lI).
The newly synthesized complexes, unlike the free ligands, act as effective antifungal agents against
Aspergillus and Candida spp., some of them showing activities comparable to ketoconazole, with minimum
inhibitory concentrations in the range of 0.3 -0.5 lug/mL. The mechanism of antifungal action of these
complexes seems to be not connected with the inhibition of lanosterol-14-o-demethylase, since the levels of
sterols assessed in the fungi cultures were equal in the absence or in the presence of the tested compounds.
Probably the new complexes act as inhibitors of phosphomannose isomerase, a key enzyme in the
biosynthesis of yeast cell walls.
Introduction
Several important classes of antifungal compounds are presently available,
5 such as the azoles
inhibiting lanosterol-14-c-demethylase,
14 sterol-A4-reductase, or AV-A isomerase as well as the inhibitors
of the zinc enzymes phosphomannose isomerase,6’b or topoisomerase.
6 All these enzymes are involved in
the biosynthesis of fungi/yeast cell walls, and their inhibition leads to impaired function of the membrane and
as a consequence death of the pathogenic species. Recently, some metal complexes such as silver
sulfadiazine were shown to possess effective antifungal properties against the pathogenic yeast Candida
albicans.
’7s The mechanism of action of this complex seems to be connected with the inhibition of
phosphomannose isomerase, a key enzyme in the biosynthesis of yeast cell walls.
6.v.s
Since resistance to the different antifungal agents constantly emerges,
2491 it is important to
investigate new types of compounds, able to prevent this serious medicalsproblem. Metal complexes,
containing mainly Ag(I) and Zn(II) seem to be a valuable such alternative.
7"s’-’ Indeed, silver sulfadiazine
is extensively used clinically for the prophylaxis and treatment of bacterial and fungal burn infections, alone
or in combination with mafenide acetate 2, as well as cerium(IV) nitrate,s’-5
Ag\ N
H2N’/’ xO
\
AcOH
H
1 2
Considering compound as lead molecule, we prepared some new derivatives of sulfacetamide 3,
another widely used clinical agent,
6 by its reaction with arylsulfonyl isocyanates of type 4. v The conjugate
bases of the new derivatives 5-9 were then used as ligands for the preparation of the Ag(I) and Zn(II)
complexes 10-19. The new compounds and their complexes were assayed for their antifungal properties
against two Aspergillus and one Candida albicans strains.
Materials and Methods
Elemental analyses were done by combustion with a Carlo Erba Instrument or gravimetrically for
the metal ions. NMR spectra have been recorded at 200 MHz, with a Varian Gemmini 200
spectrophotometer; chemical shifts are reported as 5 values, relative to Me4Si as external standard, in
solvents specified in each case. IR spectra were recorded with a Perkin-Elmer spectrophotometer using KBr
pellets as reference. Conductimetric measurements were done at room temperature on a Radelkis KFT
conductimeter.
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Sulfacetamide, sulfadiazine, mafenide hydrochloride, arylsulfonyl isocyanates, metal salts and
solvents were commercially available (from Sigma, Aldrich or Janssen) and were used without further
purification.
Generalprocedurefor preparation ofarylsulfonylureido sulfacetamides 5-9
An amount of 2.15 g (10 raM) of sulfacetamide was suspended in 100 mL of highly anhydrous (kept on
molecular sieves) acetonitrile and magnetically stirred at 4C for 10 rain. The stoichiometric amount of
arylsulfonyl isocyanate 4 (eventually dissolved in the same solvent for the solid compounds, or in pure state
for the liquid ones) was then added dropwise, maintaining the temperature under 10 C. The reaction mixture
was stirred at room temperature for 2-4 h (tic control), then the’solvent was evaporated in vacuo and the
residue crystallized from ethanol-water. Yields were practically quantitative.
4-(Benzenesulfonylamidocarbonyl)-sulfacetamide, 5: colorless crystals, mp 295-6 C (dec.). IR(KBr), cm:
SO sym 1128 and 1176 }NH ), 1290 (amide III), 1355 and 1382 (SOz"S), 1520 and 1540 (amide II); 1680 (amide I),
3065 and 3190 ); H-NMR (DMSO-d6), 5, ppm" 2.75 (s, 3H, AcN); 7.05 7.65 (m, 5H, Ph); 7.46-8.10
(m, AA’BB’, JAB 7.6 Hz, 4H, C6H4SO2); 7.94 (s, 1H, SOzNH); 8.40 (s, 1H, CONH-); 10.63 (br s, 1H,
SOzNH); Analysis, found: C, 45.50; H, 3.92; N, 10.43 %; ClsHIsN306S2 requires: C, 45.33; H, 3.80; N, 10.54
%.
4-(4-Fluorobenzenesulfonylamidocarbonyl)-sulfacetamide, 6: colorless crystals, mp 250-2 C (dec.).
IR(KBr), cml" 1 130 and 1175 (SO_sym),,1291 (amide III), 1355 and 1380 (SOzaS), 1520 and 1540 (amide II);
1680 (amide I), 3065 and 3190 (NH); ’H-NMR (DMSO-d6), 5, ppm: 2.77 (s, 3H, AcN); 7.02 7.50 (m,
AA’BB’, JAB 7.1 Hz, 4H, p-F-phenylene); 7.55 -8.14 (m, AA’BB’, JAB 7.6 Hz, 4H, C6H4SO2); 7.98 (s, 1H,
SOzNH); 8.44 (s, 1H, CONH-); 10.60 (br s, 1H, SOzNHc); Analysis, found: C, 43.24; H, 3.25; N, 10.09 %;
CsHI4FN306S_ requires: C, 43.37; H, 3.40; N, 10.12 %.
4-(4-Chlorobenzenesulfonylamidocarbonyl)-sulfacetamide, 7: colorless crystals, mp 269-70 C (dec.).
IR(KBr), cm" 135 and 1174 (SOzsym), 1290 (amide III), 1354 and 1378 (sozas), 1520 and 1540 (amide II);
1680 (amide I), 3065 and 3190 (NH); H-NMR (DMSO-d6), i, ppm: 2.75 (s, 3H, AcN); 7.02 7.53 (m,
AA’BB’, JAB 7.2 Hz, 4H, p-Cl-phenylene); 7.57 -8.11 (m, AA’BB’, JAB 7.6 Hz, 4H, C6H4SO2); 7.96 (s,
1H, SOzNH); 8.41 (s, 1H, CONH); 10.58 (br s, 1H, SOzNH); Analysis, found: C, 41.54; H, 3.47; N, 9.60 %;
CHI4CIN306Sz requires: C, 41.72; H, 3.27; N, 9.73 %.
4-(4-Tosylamidocarbonyl)-sulfacetamide, 8: colorless crystals, mp 280-2 C (dec.). IR(KBr), cm’: 1125 and
1176 (SOzSym), 1290 (amide III), 1355 and 1380 (SOz"S), 1520 and 1540 (amide If); 1680 (amide I), 3065 and
3190 (NH); "H-NMR (DMSO-d6), , ppm: 2.50 (s, 3H, p-tosyl); 2.75 (s, 3H, AcNH); 7.05 7.59 (m,
AA’BB’, JAB 7.2 Hz, 4H, phenylene from tosyl); 7.46-8.08 (m, AA’BB’, JAB 7.6 Hz, 4H, C6H4SO2); 7.91
(s, 1H, SO.NH); 8.42 (s, 1H, CONH); 10.69 (br s, 1H, SOzN/’D; Analysis, found: C, 46.50; H, 3.98; N, 10.25
%; CI6HI7N306S2 requires: C, 46.71; H, 4.16; N, 10.21%.
4-(2-Tosylamidocarbonyl)-sulfacetamide, 9: colorless crystals, mp 213-4 oC. IR(KBr), cmt: 1134 and 1173
(SOzSy")), 1290 (amide III), 1341 and 1380 (sozas), 1520 and 1540 (amide II); 1680 (amide I), 3065 and 3190
(NH); ’H-NMR (DMSO-d6), i, ppm" 2.59 (s, 3H, o-tosyl); 2.75 (s, 3H, AcN); 7.05 7.76 (m, 4H, phenylene
from o-tosyl); 7.49 -8.06 (m, AA’BB’, JAB 7.6 Hz, 4H, ArH from C6H4SO2); 7.95 (s, 1H, SOzNH); 8.50 (s,
1H, CONH); 10.62 (br s, 1H, SOzNH); Analysis, found: C, 46.87; H, 4.22; N, 10.13 %; CI6HIyN30682
requires: C, 46.71; H, 4.16; N, 10.21%.
General procedurefor the preparation ofcomplexes O- 19
An amount of 6 mmol of sodium salt of sulfonamides 5-9 was prepared by reacting the corresponding
sulfonamide with the required amount of an alcoholic IN NaOH solution, in ethanol as solvent. To this
solution was added the aqueous metal salt solution (Zn(II), Ag(l) nitrates), working in molar ratios
sulfacetamide derivative: ’’+ w or 2:1 for the zinc compounds, and 1:1 for the silver derivatives, respectively.
The aqueous-alcoholic reaction mixture was heated on a steam bath for one hour, adjusting the pH at 7 if
necessary, and after being cooled at 0 C the precipitated complexes were filtered and thoroughly washed
with alcohol-water 1:1 (v/v) and air dried. Yields were in the range of 85-90 %. The obtained white or
yellowish powders of compounds 10-19 melted with decomposition at temperatures higher than 350 C, and
were poorly soluble in water and alcohol, but had good solubilities in DMSO, DMF as well as mixtures of
DMSO-water, DMF-water.
Assay offimgistatic activity ofcompounds 1-19
The fungistatic activity was determined by a modification of the growth method recently reported,
82
utilizing two Aspergillus and one Candida spp. Minimum inhibitory concentrations (MICs) have been
determined by the agar dilution method with Iso-Sensitest agar as described by Kifisman et al.
22 The
fungi/moulds were cultivated in agar plates at 37C for 5 days, in the nutrient broth (NB, Diagnostic Pasteur),
in the absence and in the presence of 100 0.01 lug/mL of compounds 1-19. Stock solutions of inhibitors
were obtained in DMSO (100 mg/mL) and dilutions up to 0.01 btg/mL were done with distilled deionized
water. The minimum concentration at which no growth was observed was taken as MIC value (lug/mL), and
represents the mean of at least two determinations.
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Assay ofsterols present in thefungi cultures
A reverse-phase HPLC method adapted from the literature,-
has been used to determine the amount of
sterols (ergosterol and [anosterol) present in the fungi cultures. The fungi have been cultivated as mentioned
above for 5 days, with or without inhibitors added in the nutrient broth. Culture media were suspended in a
small volume of MOPS buffer (pH 7.4) and the cells centrifuged at 20000g for 30 rain. Cells were weighed
(wet paste) and broken by sonication. Sterols present in the homogenate were then extracted in chloroform,
the solvent has been evaporated to a small volume and the extracts applied on a la-Bondapak-Cl8 column,
with acetonitrile as eluting solvent. Authentic ergosterol and lanosterol (from Sigma) were used as standards.
The flow rate was of 3 mL/min. The retention times were: 8.87 rain for ergosterol; and 7.62 rain for
lanosterol, respectively. Blank assay were done for cultures which were not treated with inhibitors in order to
assess the normal levels of sterols present. The amount of ergosterol tresent in the same amount of wet cells
from the culture grown in the absence of inhibitor was taken as 100%.
21"24
Results and Discussion
Reaction of sulfacetamide 3 with arylsulfonyl isocyanates 4, afforded the ureido derivatives 5-9, by
the procedure already reported previously by this group.
7 The new compounds obtained as outlined in
Scheme 1, were characterized by spectroscopic and analytic data that confirmed their structures.
Metal complexes 6-11 containing the conjugate base of sulfonamides 5-9 (LH) and Ag(1) or Zn(lI)
ions, of types 10-19, were also obtained (Scheme 1), and their elemental analysis data are shown in Table I.
O
O=S=O EtONa
AgL
AgNO3 10-14
+ ArSO2NCO
4 Zn(NO)
NH 2 O,,,,,.NH = ZnL2
EtONa
3 HL X HNs,,O 15-19
7 4-CI 5-9 8 4-Me
9 2-Me (HL) Scheme 1
The new complexes have been characterized by spectroscopic, conductimetric and thermogravimetric
measurements (Table II). By comparing the IR spectra of the complexes and the free ligand, the following
differences were evidenced: (i) the shift of the two sulfonamido vibrations (both the symmetric as well as the
asymmetric one) belonging to the SO2NHAc moiety (at 1173-1176 cm, and 1378-1382 cm") towards lower
wavenumbers in the spectra of the complexes, as compared to the spectra of the corresponding ligand (Table
5.9 II), as already documented previously for similar complexes.- One should note that only one pair of such
vibrations underwent the above-mentioned shift, presumably those of the SO2NHAc moiety, whereas the
second sulfonamide (X-C6H4SO_NHCONH) moiety appeared at the same wavenumbers both in ligands as
well as in their metal complexes (data not shown). This is a direct indication that the deprotonated SO_NHAc
moiety of the ligand interacts with the metal ions in the newly prepared coordination compounds; (ii) the
acetamide stretching vibration in the spectra of the prepared complexes are shifted with 15-20 cm towards
lower wavenumbers, as compared to the same vibration in the spectrum of sulfonamides 5-9 indicating again
that this moiety is probably in the vicinity of the metal ions (data not shown); (iii) the ureido vibration in the
spectra of complexes 10-19, assigned as the intense band at 1680 cm appear at the same wavelength as that
of the corresponding free ligands (Table II), suggesting that these moieties do not participate in the
coordination of the metal ions.
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Table I: Complexes 10-19, containing the conjugate base of sulfonamides 5-9 (LH) as ligand and their
elemental analysis data.
No. Complex Ligand
(LH)
Analysis (ca!culated/found)
%M %C %H %N
b
10 [AgL] 5 21.39/21.50 35.73/35.61 2.80/2.71 8.33/8.30
11 [AgL] 6 20.65/20.32 34.50/34.29 2.51/2.36 8.05/7.84
12 [AgL] 7 20.02/20.30 33.44/33.25 2.43/2.21 7.80/7.51
13 [AgL] 8 20.81/20.64 37.08/36.92 3.11/3.19 8.11/8.03
14 [AgL] 9 20.81/20.49 37.08/37.15 3.11/3.45 8.11/7.87
15 [ZnL2] 5 7.62/7.45 41.99/42.26 3.28/3.07 9.79/9.63
16 [ZnL2] 6 5.06/5.35 41.85/41.71 3.20/3.37 9.76/9.69
17 [ZnL_] 7 4.94/4.72 40.81/40.96 3.12/3.38 9.52/9.43
18 [ZnL_] 8 5.09/5.40 43.98/43.62 3.69/3.54 9.82/9.67
19 [ZnL_] 9 5.09/4.96 43.98/43.95 3.69/3.77 9.82/9.71
aBy gravimetry; bBy combustion.
One may reach the same conclusion by studying the H-NMR spectra of the Ag(I) and Zn(II)
complexes, as compared to the corresponding spectra of the ligands. Thus, the only difference between the
two types of spectra concerns the signal of the methyl group of the AcNHSO2 moiety, which in the
complexes appears at 2.55 2.68 ppm, whereas in the ligands at 2.75-2.77 ppm (Table II). Similar behaviors
were also evidenced previously for other sulfonamide metal complexes, by our group,
,_5-29 and probably
indicate that this methyl moiety is in the vicinity of the zinc/silver ions in the prepared complexes.
Conductometric data (Table II) also indicate that the new complexes 10-19 are non-electrolytes, being
undissociated in DMF (or DMSO) as solvent.
Biological activity data with the new derivatives 1-19 and the standard azole antifungal agent
ketoconazole 20 are shown in Table III.
Table II: Spectroscopic, thermogravimetric and conductimetric data for compounds 4-11.
Comp. IR Spectra ,cm
V (SO2)S v (SO2)as v (C=O)
H-NMR spectrab
8, ppm (Me ofAcNHSO2)
Condu.tomeWy
AM (g2" x cm’x tool")
10 ll61 1368 1680 2.64 3
11 1158 1366 1680 2.63 6
12 1157 1365 1680 2.68 6
13 1160 1365 1680 2.61 5
14 1159 1365 1680 2.62 5
15 1155 1360 1680 2.60 4
16 1154 1360 1680 2.57 8
17 1155 1357 1680 2.55 3
18 1155 1356 1680 2.58 4
19 1154 1361 1680 2.57 6
In KBr; bin DMSO, at 25 C; mM solution, in DMF, at 25C; a Probably the ureido NHCONH vibration.
From data of Table III, one should note that the new complexes 10-19 reported here represent a new
class of antifungals with MIC-s (minor inhibitory concentration) in the micromolar range, which might
induce strong in vivo antifungal effects. Furthermore, the ligands from which the complexes were prepared,
as well as the related sulfonamide 2, are devoid of such antifungal properties, against the three strains
investigated here. The most active derivative were the Ag(I) complexes 10-14, followed by the Zn(II) ones
containing the same type of ligand. From this point of view, the halogeno-substituted ligands led to more
active antifungal complexes as compared to the phenyl- and tosyl-ureido derivatives. Candida was most
susceptible to inhibition, followed by A. flavus, whereas A. niger was the most resistant to this type of
antifungals. In this respect, the complex derivative parallel the biological activity of ketoconazole, although
they are less active. One should anyhow note that some of our new complexes are more active antifungals
than silver sulfadiazine 1, a clinically widely used derivative (Table III).
Ketoconazole 20 is known to act as an inhibitor of lanosterol 14-c-demethylase (CYP51A1), a
microsomal cytochrome P-450 dependent enzyme system belonging to a gene superfamily involved in sterol
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biosynthesis in fungi, plants and animals.
24 CYP51A1 has been shown to catalyze the conversion of
lanosterol to the 14-desmethylated derivative, ergosterol, through a complicated oxidative sequence. Its
inhibition in fungi causes the depletion of ergosterol and accumulation of 14-methylsterols in the membrane
of the cells, disturbing thus membrane function and causing the death of these organisms.
24
Table III" Antifungal activity of compounds 1-19 against several organisms.
Compound MIC (lag/mL)
A. flavus C 1150 A. niger C418 Candid2 albicans C316
20 23 8
2 > 100 > 100 > 100
3 > 100 > 100 > 100
5 > 100 > 100 > 100
6 > 100 > 100 > 100
7 > O0 > O0 > O0
8 95 > 100 84
9 88 >100 87
10 12 13 2.5
11 9 10 1.8
12 3 5 1.9
13 5 7 2.4
14 9 10 2.8
15 22 29 6
16 18 24 5
17 13 25 5
18 21 27 9
19 18 19 11
Ketoeonazole 20 1.2 1.8 0.06
Thus, in order to investigate whether the complexes reported here act as ergosterol biosynthesis
inhibitors, similarly to the azole antifungals, the amounts of ergosterol present in C. albicans cultures after
treatment with different concentrations of the new the inhibitor 11 and ketoconazole 20, a potent CYP51A1
inhibitor,
2 have been determined by means of a HPLC method (Table IV).
23
Table IV’ Levels of ergosterol in C. albicans cultures after treatment with different concentrations of the
azole CYP51AI inhibitor ketoconazole 20 and the silver complex 11.
Inhibitor Concentration % Ergosterol*
(lag/mL)
Ketoconazole 0.01 89 + 5
Ketoconazole 0.02 66 + 7
Ketoconazole 0.05 8 + 4
11 0.25 99 +
0.50 98 + 2
11 1.00 98 + 2
11 1.50 99 + 2
*Mean + standard deviation (n 3); The amount of ergosterol present in the same amount of wet cells from
the culture grown in the absence of inhibitor is taken as 100 %.
The data of Table IV show that, in contrast to ketoconazole, the silver complex investigated here,
1, does not act as inhibitor of CYP51A1, possessing thus a different mechanism of antifungal action.
Probably, as many other Ag(1) derivatives, the new antifungals might exert their effects through poisoning
some components of the respiratory enzymes in the fung,al/microbial electron transport system, or even
through interaction with the DNA of the pathogenic species.
"3
In conclusion we report here the preparation and antifungal activity of some Ag(I) and Zn(II)
complexes of sulfacetamide derivatives, possessing interesting biological activity against several Aspergilhts
and Candida strains.
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